Schnell to conduct Phase I trial for biosimilar drug

Published: 2011-07-13 06:57:00
Updated: 2011-07-13 06:57:00
Schnell Biopharmaceutical said it will carry out its Phase 1 clinical trial for its arthritis biosimilar after recent approval from the Korea Food and Drug Administration.

Schnell plans to develop and commercialize the drug candidate named GS 071 together with Japan’s Nichi-Iko Pharmaceuticals...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.